Immunization antibody response

B-Cell Immune Antibody response represents the first line of defense against most... 

The active immunotherapeutic approach is specific and based on the premise that tumor antigens are immunogenic and the host is sufficientiy immunocompetent to mount an effective immune response to an autologous tumor. Theoretically, a weak or suppressed host immune system that had allowed the formation of a tumor may be overridden by active immunization or immunostimulation. In practice, vaccines composed of so-called autologous tumor extracts have been used to treat patients with malignant melanoma (73), and purified melanoma tumor-associated antigens have been used to ehcit antibody responses in melanoma patients (74). 

A number of chimerized, humanized, and one human mAb have now been approved for therapeutic use in humans in the treatment of autoimmunity, malignancy, infection and cardiovascular disease (Table 1). Some of the currently licensed mAb will be discussed here. A much larger number of mAb are currently being evaluated in Phase I, II and III trials. In general, chimeric, humanized and human mAb are very well tolerated with few side effects. Chimeric or humanized mAb still have the potential to evoke host immune response to the variable domains or CDRs of the antibody so-called HACA (human anti-chimeric antibody) or HAHA (human anti-human antibody) responses, although these responses are uncommon. Short-lived and occasionally severe infusion-related acute hypersensitivity reactions such as fever, skin itching, shivering, respiratory compromise and low blood pressure sometimes occur-. Such effects may... 

Rat DBTC 4-6 weeks at 0, 50, and 150 mg/kg diet = 0, 2.5, and 7.5 mg/kg body weight Decrease in ceiiuiar and humorai immune response, in haemaggiutination and haemoiysin titres suppression of primary antibody response against sheep red biood ceiis Lowest dose at which effects were reported = 2.5 Seinen et al. (1977b)... 

Two goats were immunized three times during the first 2 weeks with 1 mg of the antigen emulsified in 1 ml of Freund s complete adjuvant at several subcutaneous sites near regional lymph centers. Booster injections of 3 mg of antigen were administered at monthly intervals. The animals were bled 7 days after each boost. After several months of immunization, the titer and affinity of the antibody response was judged sufficient for use. 

Lymphocyte 20-40% T cells (cell-mediated immunity) B cells (humoral antibody response) Lymphocytosis Viral infections (e.g., mononucleosis) Tuberculosis Fungal infections Lymphopenia human immunodeficiency virus... 

Figure 4. Comparison of Freund s Adjuvant to Adjuvax formulations in stimulating antibody response to P55 oligopeptide antigen. Relative antibody titers between adjuvant groups at day 27 were determined by measuring the absorbance at 450 nm of a 1 500 dilution of anti-P55 immune sera by ELISA.

Pantarotto, D. et al. (2003) Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem. Biol, 10, 961-966. 

The indications are that gut antigen-based vaccines, at least based on the antigens described above and mediated by high systemic antibody responses, are unlikely to be wholly effective against non-blood-feeding nematodes. Different antigens may be required and may need to be delivered in such a way as to stimulate local mucosal immune responses. 

It has already been noted that the phenotype of an acquired immune response is considered to reflect the early cytokine environment in which naive CD4+ T cells interact with antigen. Again, it has been suggested, for example, that early exposure to IL-4 can push an immune response in a Th-2 direction (Swain et al., 1990). We therefore investigated (by ELISA) whether ES-62 was able spontaneously to induce IL-4 secretion in naive murine spleen cells (48 h exposure). Ironically, given that the molecule induces a Th-2 antibody response and seems to be able to induce the release of a number of other cytokines, IL-4 was not detected (Harnett et al., 1999a). It was noted, however, that IL-4 was produced by spleen cells from mice that had been pre-exposed to ES-62. This established Th-2 phenotype is consistent with the antibody data. 

Mitchell, G.F. and Lewers, H.M. (1976) Studies on immune responses to parasite antigens in mice IV. Inhibition of an anti-DNP antibody response with antigen, DNP-Ficoll containing phosphorylcholine. International Archives of Allergy and Applied Immunology 52, 235—240. 

Raising the pi of macromolecules also can significantly alter the immune response toward them upon in vivo administration. Cationized proteins (those modified with diamines to increase their net charge or pi) are known to generate an increased immune response compared to their native forms (Muckerheide et al., 1987a, b Apple et al., 1988 Domen et al., 1987 Domen and Hermanson, 1992). The use of cationized BSA as a carrier protein for hapten conjugation can result in a dramatically higher antibody response toward a coupled hapten (Chapter 19). 

In an immune response, antibodies are produced and secreted by the B-lymphocytes in conjunction with the T, cells. In the majority of hapten-carrier systems, the B cells end up producing antibodies that are specific for both the hapten and the carrier. In these cases, the T lymphocytes will have specific-binding domains on the carrier, but will not recognize the hapten alone. In a kind of synergism, the B- and T-cells cooperate to induce a hapten-specific antibody response. After such an immune response has taken place, if the host is subsequently challenged with only the hapten, usually it will respond by producing hapten-specific antibodies from memory cells formed after the initial immunization. For a review of immunobiology (see Janeway, 2004). 

---